The Anita Bhatia Foundation for Tomorrow has announced a $500,000 investment over three years to the TSC Alliance, to transform the landscape for families navigating Tuberous Sclerosis Complex (TSC).
The multiyear philanthropic commitment is designed to bridge the gap between scientific data and the daily realities of patients living with this rare genetic disease.
The funding primarily targets TSC Associated Neuropsychiatric Disorders (TAND), a complex spectrum of cognitive and behavioral challenges, including autism, that often impact patients more severely than the physical tumors associated with the condition.
By focusing on TAND, the foundation aims to provide families with a roadmap grounded in rigorous evidence rather than the uncertainty that can often stall clinical progress.
This partnership carries a significant connection to the Indian American community. The Anita Bhatia Foundation for Tomorrow is an evolution of nearly two decades of philanthropic leadership rooted in the Ramesh and Kalpana Bhatia Family Foundation, established in 2006.
Ramesh and Kalpana Bhatia, who immigrated to the United States from India, built a legacy of giving that their daughter, Anita Bhatia, now spearheads. Anita, an experienced health administrator, has transitioned the family’s mission into a focused effort to remove structural barriers in healthcare.
A significant portion of the new grant will fund the 2026 International TSC Clinical Consensus Conference. This global gathering of experts is critical for updating diagnostic criteria and management recommendations used by clinicians worldwide.
Read: Seattle University’s Mehta Wahi law scholarship targets barriers for international students
Furthermore, the investment will bolster “Anya’s Accelerator” through 2028. This initiative was launched in 2022 following a record-breaking $2.5 million gift from the family, inspired by Anita’s daughter, Anya, who was diagnosed with TSC as an infant. The accelerator focuses on developing biomarkersm biological indicators that could allow doctors to diagnose TAND manifestations earlier.
“This investment reflects our commitment to accelerating discovery, strengthening hope, and ensuring that every family affected by TSC has access to knowledge and treatments,” Anita Bhatia stated, emphasizing that the foundation’s work is driven by a belief in data-led solutions.
For many families, the struggle with TSC is defined by the unknown. Because the disease affects brain function in unpredictable ways, parents often wait years for an accurate neuropsychiatric diagnosis.
The TSC Alliance intends to use this new capital to establish a “Core Outcome Measure Set,” providing a universal yardstick for clinicians to track disease progression and response to therapy.
Kari Luther Rosbeck, President and CEO of the TSC Alliance, noted that TAND remains one of the greatest unmet needs in the community. By validating a blood-based biomarker panel, researchers hope to move toward a future where a simple test can provide the answers that families currently spend years searching for.